Non-dystrophic myotonia Chilean cohort with predominance of the SCN4A Gly1306Glu variant

Avila-Smirnow, Daniela, Vargas, Carmen, Beytia, Maria de los Angeles; , Cortez R, Escobar R, et al

Keywords: carbamazepine, myotonia congenita, founder effect, apnoea, strabismus, Laryngospasm

Abstract

Non-dystrophic myotonias are a group of rare neuromuscular diseases linked to SCN4A or CLCN1. Among the subtypes, myotonia permanens, associated with the Gly1306Glu variant of SCN4A, is a relatively less frequent but more severe form. Most reports of non-dystrophic myotonias describe European populations. Therefore, to expand the genetic and phenotypic spectrum of this disorder, we evaluated 30 Chilean patients with non-dystrophic myotonias for associated variants and clinical characteristics. SCN4A variants were observed in 28 (93%) of patients, including 25 (83%) with myotonia permanens due to the Gly1306Glu variant. Myotonia permanens was inherited in 24 (96%) patients; the mean age of onset was 6 months, and the initial symptoms were orbicularis oculi myotonia in 17 (74%) patients and larynx myotonia in 12 (52%) patients. The extraocular muscles were involved in 11 (44%) patients, upper limbs in 20 (80%), and lower limbs in 21 (84%). Thirteen (52%) patients experienced recurrent pain and 10 (40%) patients reported limitations in daily life activities. Carbamazepine reduced myotonia in eight treated patients. The high frequency of the Gly1306Glu variant in SCN4A in Chilean patients suggests a founder effect and expands its phenotypic spectrum.

Más información

Título de la Revista: NEUROMUSCULAR DISORDERS
Volumen: 30
Editorial: PERGAMON-ELSEVIER SCIENCE LTD
Fecha de publicación: 2020
Página de inicio: 554
Página final: 561
Idioma: inglés
URL: https://pubmed-ncbi-nlm-nih-gov.pucdechile.idm.oclc.org/28733338/